genentech Archives - GO2 for Lung Cancer

GO2 for Lung Cancer Leads Study to Improve Participation of Black Communities in Lung Cancer Clinical Trials

SAN CARLOS, Calif. and WASHINGTON – GO2 for Lung Cancer (GO2 for Lung Cancer) announced its leadership in the launch of an important multi-institutional study to determine how to improve the participation of Black communities in lung cancer clinical [...]

FDA Approves Tecentriq Plus Chemotherapy as a First-Line Treatment for Metastatic NSCLC

Bethany Johnson (GO2 for Lung Cancer)2020-04-17T11:45:34-05:00December 5th, 2019|Hot Topics, News, Press Releases, Science and Research|

On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no [...]